Articles written by Vandana Singh - Benzinga

Waldencast Q4 Earnings Preview: All Eyes On Tariff Impact, Obagi Skincare Brand

|Waldencast is set to report Q4 earnings, with analysts projecting $81.69M sales. The company expands Obagi globally while mitigating potential tariff impacts.

Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside

|Needham starts coverage on Ocular Therapeutix with a Buy rating, citing Axpaxli's potential in wet AMD and forecasting $1.5 billion peak sales.

Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue

|CMS approves ADLT status for Guardant Health's Shield test, setting Medicare reimbursement at $1,495. The analyst sees a potential revenue boost from the decision.

Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes

|Goldman Sachs upgrades GE Healthcare to Buy, raising its price target to $100, as analysts see market stabilization and China sales recovering faster than expected.

Diagnostic Kit Maker Illumina To Cut $100 Million In Costs, Lowers 2025 Profit Outlook Amid China Trade Restrictions

|Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for high-single-digit growth by 2027.

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

|Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

Merck Injects $1 Billion To Expand Vaccine Production In US

|Merck unveils a $1 billion vaccine manufacturing facility in Durham, North Carolina, expanding its U.S. production and research investments.

Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

|Bioventus posted strong Q4 results, with EPS and revenue surpassing estimates. The company projects 2025 sales of $560M–$570M and adjusted EPS of $0.64–$0.68.

Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal

|Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025.

Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair Loss

|Eli Lilly and Incyte's baricitinib showed significant hair regrowth in adolescents with severe alopecia areata, with results comparable to adults at 52 weeks.

Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial

|Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.

EXCLUSIVE: Alzamend Neuro To Launch Phase 2 Study For Lead Drug For PTSD Patients In Late 2025 To Assess Lithium Delivery Benefits

|Alzamend Neuro plans a Phase 2 trial of AL001 for PTSD in late 2025, aiming for better lithium delivery, improved safety, and reduced systemic side effects.

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

|Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.

Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate

|Mineralys Therapeutics' lorundrostat met key Phase 3 and Phase 2 trial endpoints for hypertension, showing significant blood pressure reductions and a strong safety profile.

Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps

|Incyte's Phase 3 TRuE-PN trials show ruxolitinib cream improves itch relief in prurigo nodularis, though TRuE-PN2's primary endpoint fell short.

Bristol Myers Unveils Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis

|Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16.

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study

|Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

|Trevi's Haduvio met the primary endpoint in a Phase 2a trial, showing a significant reduction in cough frequency with no serious adverse events reported.

India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details

|Sun Pharma to acquire Checkpoint Therapeutics for $4.10 per share, with potential CVR. FDA approves Unloxcyt, the first PD-L1 blocker for advanced cSCC.

Pfizer's COVID-19 Shot Partner BioNTech Reports Q4 Profit, But 2025 Guidance Falls Short On Expectations

|BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025.